Plataforma Affymetrix de Microarrays (PAM)

  • PAM

PAM is an Affymetrix European Reference Group Cytogenetic applications and participates in the Cytogenetic European Quality Assessment (CEQA)

Affymetrix® Microarrays Platform (PAM) is a service focused on DNA and RNA microarray solutions offered by Affymetrix. Solutions towards a personalized medicine.

Molecular cytogenetics

Microarray studies can offer various solutions for cytogenetic applications:

  • Detection of whole genome gains and losses at a high resolution.
  • Analysis of whole genome absences of heterozygosity.
  • SNPs genotyping and genome-wide association studies.

RNA Analysis Solution

Gene expression profile studies on either human or mouse are suitable for:

  • Detection of genes and pathways involved in diseases, treatment responses and biological processes.
  • Predictive models based on gene expression profiles.
  • Pharmacogenomics and toxicogenomics studies.
  • Alternative splicing detection.
  • Classification of samples on gene signatures.
  • Analysis of miRNA.
  • Microarray analysis on compromised samples with degraded and/or low quantity samples.

Quality sample analysis

In addition, to the microarray procedure we also offer DNA and RNA quantification and quality control analysis.


1. Nicolle D, Fabre M, Simon-Coma M, Gorse A, Kappler R, Nonell L, Mallo M, Haidar H, Déas O, Mussini C, Guettier C, Redon MJ, Brugières L, Rosa Ghigna M, Fadel E, Galmiche-Rolland L, Chardot C, Judde JG, Armengol C, Branchereau S, Cairo S. Patient-derived xenografts from pediatric liver cancer predict tumor recurrence and advise clinical management. Hepatology. 2016 Apr 26. doi: 10.1002/hep.28621. FI: 11.055 (2014).

2. Palomo L, Xicoy B, Garcia O, Mallo M, Ademà V, Cabezón M, Arnan M, Pomares H, Larrayoz Mj, Calasanz Mj, Maciejewski Jp, Huang D, Shih Ly, Ogawa S, Cervera J, Such E, Coll R, Grau J, Solé F, Zamora L. Impact of SNP array karyotyping on the diagnosis and the outcome of chronic myelomonocytic leukemia with low risk cytogenetic features or no metaphases. Am J Hematol. 2015. doi: 10.1002/ajh.24227. FI: 3.798 (2014).

3. McGraw KL, Zhang LM, Rollison DE, Basiorka AA, Fulp W, Rawal B, Jerez A, Billingsley DL, Lin HY, Kurtin SE, Yoder S, Zhang Y, Guinta K, Mallo M, Solé F, Calasanz MJ, Cervera J, Such E, González T, Nevill TJ, Haferlach T, Smith AE, Kulasekararaj A, Mufti G, Karsan A, Maciejewski JP, Sokol L, Epling-Burnette PK, Wei S, List AF. The relationship of TP53 R72P polymorphism to disease outcome and TP53 mutation in myelodysplastic syndromes. Blood Cancer J. 2015; 13;5:e291. F.I: 3.467 (2014).

4. Arenillas L, Mallo M, Ramos F, Guinta K, Barragán E, Lumbreras E, Larráyoz MJ, De Paz R, Tormo M, Abáigar M, Pedro C, Cervera J, Such E, Calasanz MJ, Díez-Campelo M, Sanz GF, Hernández JM, Luño E, Saumell S, Maciejewski J, Florensa L, Solé F. Single nucleotide polymorphism array karyotyping: A diagnostic and prognostic tool in myelodysplastic syndromes with unsuccessful conventional cytogenetic testing. Genes Chromosomes Cancer 2013; 52: 1167-1177. F.I: 3.836.

5. Mallo M, Del Rey M, Ibáñez M, Calasanz MJ, Arenillas L, Larráyoz MJ, Pedro C, Jerez A, Maciejewski J, Costa D, Nomdedeu M, Diez-Campelo M, Lumbreras E, González-Martínez T, Marugán I, Such E, Cervera J, Cigudosa JC, Alvarez S, Florensa L, Hernández JM, Solé F. Response to lenalidomide in myelodysplastic syndromes with del(5q): influence of cytogenetics and mutations. Br J Haematol. 2013 Jul;162(1):74-86. F.I: 4.942.

6. Villa O, Mallo M, Kosyakova N, Salido M, Liehr T, Martínez-Avilés L, Pedro C, García-Aragonés M, Espinet B, Bellosillo B, Florensa L, Arenillas L, Cuscó I, Jurado LA, Solé F. Deletion of TET2 gene in an acute myeloid leukemia case with a t(4;15)(q24;q26) characterized by glass needle based chromosome microdissection and oligonucleotide array. Leuk Res 2011; 35(9): e161-e163. F.I: 2.923.